2011 Canadian hypertension education program recommendations: An annual update

Canadian Family Physician

Volumn 57, Issue 12, 2011, Pages 1393-1397

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT;

BLOOD PRESSURE MEASUREMENT; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; FIBRINOLYTIC THERAPY; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICAL EDUCATION; NEOPLASM; PATIENT CARE; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CANADA; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEALTH EDUCATION; HEALTH POLICY; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; STROKE;

EID: 83755183760     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. World Health Organization. Global health risks: morality and burden of disease attributable to selected major risks. Geneva, Switz: World Health Organization; 2009.
2. Gaziano TA, Bitton A, Anand S, Weinstein MC. The global cost of nonoptimal blood pressure. J Hypertens 2009;27(7):1472-7.
3. Wilkins K, Campbell NR, Joffres MR, McAllister FA, Nichol M, Quach S, et al. Blood pressure in Canadian adults. Health Rep 2010;21(1):37-46.
4. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10(10 Pt 1):1097-102. (Pubitemid 27486342)
5. Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009;53(2):128-34. Epub 2008 Dec 29.
6. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR. The impact of the CHEP in its first decade. Eur Heart J 2009;30(12):1434-9. Epub 2009 May 19.
7. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22(1):11-9. (Pubitemid 38293521)
8. Campbell NR, Sheldon T. The Canadian effort to prevent and control hypertension: can other countries adopt Canadian strategies? Curr Opin Cardiol 2010;25(4):366-72.
9. Hypertension Canada [website]. About us. Markham, ON: Hypertension Canada; 2011. Available from: www.hypertension.ca/en/about-us. Accessed 2011 Oct 25.
10. Public Health Agency of Canada. Creating a healthier Canada: making prevention a priority. Ottawa, ON: Public Health Agency of Canada; 2010. Available from: www.phac-aspc.gc.ca/hp-ps/hl-mvs/declaration/indexeng. php. Accessed 2011 Oct 25.
11. Campbell NR, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, et al. Hypertension in diabetes: a call to action. Can J Cardiol 2009;25(5):299-302.
12. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005;165(12):1410-9. (Pubitemid 40973424)
13. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575-85. Epub 2010 Mar 14.
14. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33(5):1315-20. (Pubitemid 34517053)
15. Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JW, Molony DA, et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993;50(8):855-62. (Pubitemid 23229313)
16. Lindsay MP, Gubitz G, Bayley M, Hill MD, Davies-Schinkel C, Singh S, et al. Canadian best practice recommendations for stroke care. Update 2010. Ottawa, ON: Canadian Stroke Network; 2010.
17. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008;7(5):391-9. Epub 2008 Apr 7.
18. Delcourt C, Huang Y, Wang J, Heeley E, Lindley R, Stapf C, et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). Int J Stroke 2010;5(2):110-6.
19. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001;22(15):1343-52. (Pubitemid 32737627)
20. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet 2010;11(7):627-36. Epub 2010 Jun 11.
21. US Food and Drug Agency. FDA drug safety communication: ongoing safety review of the angiotensin receptor blockers and cancer. Rockville, MD: US Food and Drug Agency; 2011. Available from: www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm218845. htm#Additional-Information-for-Healthcare-Professionals. Accessed 2011 Oct 24.
22. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA 2002;287(8):1003-10. (Pubitemid 34252058)
23. Padwal RS, Hemmelgarn BR, McAlister FA, McKay DW, Grover S, Wilson T, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1 - blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 2007;23(7):529-38. (Pubitemid 46977988)
24. Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McKay DW, Wilson T, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009;25(5):279-86.
25. Anastasia S. Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil 2010;17(5):519-23.
26. Grover SA, Ilka L, Lawrence J, Mohammed K, Sylvie M, Louis C, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. Arch Intern Med 2007;167(21):2296-303.
27. D'Agostino RB, Ramachandran S, Pencina VM, Wolf PA, Cobain MR, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743-53. Epub 2008 Jan 22.
28. Khan N, Chockalingam A, Campbell NR. Lack of control of high blood pressure and treatment recommendations in Canada. Can J Cardiol 2002;18(6):657-61.
29. Campbell NR, So L, Amankwah E, Quan H, Maxwell C. Characteristics of hypertensive Canadians not receiving drug therapy. Can J Cardiol 2008;24(6):485-90.
30. Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, et al. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol 2007;23(14):1124-30. (Pubitemid 351255686)
31. McInnis NH, Fodor G, Lum-Kwong MM, Leenen FH. Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens 2008;21(11):1210-5. Epub 2008 Sep 4.
32. Ashenden R, Silagy C, Weller D. A systematic review of the effectiveness of promoting lifestyle change in general practice. Fam Pract 1997;14(2):160-76.
33. Carter BL, Doucette WR, Franciscus CL, Ardery G, Kluesner KM, Chrischilles EA. Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. Pharmacotherapy 2010;30(3):228-35.
34. Carter BL, Gail A, Dawson JD, James PA, Bergus GR, Doucette WR, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med 2009;169(21):1996-2002.
35. Sodium Working Group. Sodium reduction strategy for Canada. Ottawa, ON: Health Canada; 2010.
36. Joffres MR, Campbell NR, Manns B, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. Can J Cardiol 2007;23(6):437-43. (Pubitemid 46977999)
37. Penz ED, Joffres MR, Campbell NR. Reducing dietary sodium and decreases in cardiovascular disease in Canada. Can J Cardiol 2008;24(6):497-501.
38. Lewanczuk R. Hypertension as a chronic disease: what can be done at a regional level? Can J Cardiol 2008;24(6):483-4.
39. Karwalajtys T, Kaczorowski J. An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy. Risk Manag Healthc Policy 2010;3:39-48.
40. World Health Organization. 2008-2013 action plan for global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. Geneva, Switz: World Health Organization; 2008.
41. World Health Organization. A prioritized research agenda for prevention and control of noncommunicable diseases. Geneva, Switz: World Health Organization; 2010.
42. Smith ER. The Canadian heart health strategy and action plan. Can J Cardiol 2009;25(8):451-2.